Apptomics aims to establish its digital platform as the standard for monitoring movement disorders

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/monkeybusinessimages)
(Image: Getty/monkeybusinessimages)

Related tags: BBK, Digital biomarker, Parkinson’s disease, Clinical trials

Apptomics is working with BBK and Biotaware to develop the remote health-monitoring platform, which recently served as a digital biomarker to evaluate treatment effects as part of an essential tremor clinical trial.

Apptomics announced Monday that its digital platform E.V.A (Evaluation. Validation. Action) has been used successfully in a study for essential tremor. Researchers used the platform as an “exploratory digital biomarker”​ in addition to standard clinical scales to evaluate treatment effects.

Georgia Mitsi, PhD, MBA, Co-founder and CEO, Apptomics, told us app is being used in a sub study to look at the use of objective criteria and its role in evaluating movement disorders. 

Apptomics, which provides digital health solutions, partnered with the patient recruitment and engagement technology firm BBK Worldwide in 2016 to develop a suite of mobile apps for patients, caregivers, physicians, and payers. The company also is working with Biotaware to develop the platform, which it hopes will become the standard for monitoring movement disorders.

“BBK is an investor and has been commissioned to advance the user interface and assist in the evolution in the application,”​ Joan F. Bachenheimer, founding principal and CEO, BBK Worldwide, told us. BBK is working with Biotaware also to ensure the data integrity and the evaluation of the metrics, she said.

The E.V.A platform – originally dubbed iMotor – has been updated to include the addition of a digital spirography, a functional test of upper limb function. It also can be paired with electronic clinical outcome assessment (eCOA) and electronic data capture (EDC) platforms, according to the company.

Currently, E.V.A is being evaluated for its ability to help assess patient response to investigational treatments in a Phase III study in essential tremor as well as several Phase II studies in Parkinson’s disease and essential tremor.

Related news

Show more

Related products

show more

Efficient Clinical Supply Management & Forecasting

Efficient Clinical Supply Management & Forecasting

Catalent Pharma Solutions | 30-Nov-2021 | Insight Guide

How can clinical supply management benefit your trials? Download this eBook to explore how you can drive excellence within the forecasting process, as...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 01-Nov-2021 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Related suppliers

Follow us


View more